[1] |
LEI Yajie , GAO Yi , WANG Zhijie , CHENG Xi , YANG Yufei , ZHOU Hongyu , CHEN Lihua , CHEN Yixin , LI Haoran , LI Ziting , WU Xiaohua .
Potential role of lymphadenectomy in patients with ovarian cancer (ⅠC-ⅡA): a retrospective trial
[J]. China Oncology, 2021, 31(8): 740-745.
|
[2] |
ZHU Jun, WU Xiaohua.
Leading research progress and prospect of gynecological oncology in 2020
[J]. China Oncology, 2021, 31(4): 250-256.
|
[3] |
CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin.
Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases
[J]. China Oncology, 2021, 31(4): 330-334.
|
[4] |
LIU Yixuan , WEN Zexuan , GUO Lin , LU Renquan .
The function of TTK1 in platinum-resistant ovarian cancer
[J]. China Oncology, 2021, 31(3): 182-191.
|
[5] |
YU Yi, CONG Qing, XU Congjian, JIANG Wei.
The effect of PAFR on cisplatin sensitivity in ovarian cancer cells and its mechanism
[J]. China Oncology, 2021, 31(11): 1063-1071.
|
[6] |
WANG Zhihen , MAO Peimin , JIANG Hongyuan , FAN Lingling .
Assessment of the diagnostic value of CPH-I, CA12-5 and HE4 for cancer prediction in women with ovarian masses with papillary projections diagnosed by ultrasound
[J]. China Oncology, 2020, 30(8): 599-604.
|
[7] |
ZHAO Haiyun, WU Xiaohua.
Research progress of immunotherapy in ovarian cancer
[J]. China Oncology, 2020, 30(7): 538-545.
|
[8] |
WANG Xiaoqin, FU Xinlei, MA Ruyue, YANG Lina, CHEN Yaping, ZHANG Liwen.
Sema3A regulates metastasis through epithelial-mesenchymal transition/matrix metalloproteinase-2 in epithelial ovarian cancer
[J]. China Oncology, 2020, 30(6): 428-434.
|
[9] |
FENG Zheng, WU Xiaohua.
Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer
[J]. China Oncology, 2020, 30(4): 299-304.
|
[10] |
WU Xiaohua, ZHANG Jian, YIN Rutie, LOU Ge, GAO Yunong.
Chinese expert experience in optimizing stage Ⅰ clinical study management of ovarian cancer
[J]. China Oncology, 2019, 29(5): 321-327.
|
[11] |
WANG Jue, DU Yan, WANG Yejing, et al.
Incidence and mortality of ovarian cancer among permanent residents in the Former Luwan District of Shanghai between 2002 and 2011
[J]. China Oncology, 2018, 28(6): 407-410.
|
[12] |
GUO Fangfang, FENG Wenjuan, LI Dongqing, et al.
Clinical comparison of robotic-assisted and traditional laparoscopic operations in the treatment of early stage ovarian cancer
[J]. China Oncology, 2018, 28(2): 151-155.
|
[13] |
GAO Feifei, GUO Lei, XUE Kai, et al.
Comparison of the clinical characteristics of ovarian lymphoma and ovarian cancer with bulk lymph node involvement
[J]. China Oncology, 2017, 27(4): 281-286.
|
[14] |
FENG Xin, WANG Caixia, OU Zhiying.
Effect of recombinant human TRAIL protein combined with cisplatin on the growth and apoptosis of human ovarian cancer cells
[J]. China Oncology, 2016, 26(8): 648-654.
|
[15] |
ZHANG Pengnan, SUN Hong, JIANG Hongyuan.
Expression of miR-483-5p in epithelial ovarian cancer and its effects on cisplatin resistance in epithelial ovarian cancer cells
[J]. China Oncology, 2016, 26(5): 394-398.
|